OA11838A - Gardos channel antagonists. - Google Patents

Gardos channel antagonists. Download PDF

Info

Publication number
OA11838A
OA11838A OA1200100220A OA1200100220A OA11838A OA 11838 A OA11838 A OA 11838A OA 1200100220 A OA1200100220 A OA 1200100220A OA 1200100220 A OA1200100220 A OA 1200100220A OA 11838 A OA11838 A OA 11838A
Authority
OA
OAPI
Prior art keywords
substituent
acetamide
ring
compound
para
Prior art date
Application number
OA1200100220A
Other languages
English (en)
Inventor
Grant Andrew Mcnaughton-Smith
Gregory Cooksey Rigdon
Jonathan Walter Stocker
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of OA11838A publication Critical patent/OA11838A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA1200100220A 1999-02-23 2000-02-10 Gardos channel antagonists. OA11838A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13551199P 1999-02-23 1999-02-23
US09/386,601 US6288122B1 (en) 1999-02-23 1999-08-31 Gardos channel antagonists

Publications (1)

Publication Number Publication Date
OA11838A true OA11838A (en) 2005-08-22

Family

ID=26833406

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100220A OA11838A (en) 1999-02-23 2000-02-10 Gardos channel antagonists.

Country Status (16)

Country Link
US (1) US6288122B1 (zh)
EP (1) EP1158971B1 (zh)
JP (2) JP4038337B2 (zh)
KR (1) KR100705726B1 (zh)
CN (1) CN1193748C (zh)
AP (1) AP1465A (zh)
AT (1) ATE370728T1 (zh)
AU (1) AU762039B2 (zh)
BR (1) BR0008416A (zh)
CA (1) CA2371857C (zh)
DE (1) DE60036093T2 (zh)
ES (1) ES2291191T3 (zh)
HK (1) HK1045262B (zh)
IL (2) IL145012A0 (zh)
OA (1) OA11838A (zh)
WO (1) WO2000050026A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
US7208527B2 (en) 2002-01-04 2007-04-24 Poseidon Pharmaceuticals A/S Potassium channel modulators
US20040029771A1 (en) * 2002-02-28 2004-02-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US20070027205A1 (en) * 2003-07-03 2007-02-01 Joachim Demnitz Diarylmethyl derivatives as potassium channel modulators
WO2005003143A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Novel potassium channel modulators
EP1861356A1 (en) * 2005-02-01 2007-12-05 Icagen, Inc. Imines as ion channel modulators
CN101437403A (zh) * 2005-12-20 2009-05-20 Icagen公司 使用三芳基甲烷化合物的治疗方法
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
PT2192896E (pt) 2007-08-24 2011-04-04 Neurosearch As Derivados de carbonilamino úteis para o tratamento de doença inflamatória intestinal
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
AU2009233807B2 (en) 2008-04-09 2014-11-27 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
EP2358750B1 (en) 2008-11-10 2017-01-11 Boehringer Ingelheim International GmbH Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
US10179115B2 (en) 2015-02-20 2019-01-15 The Children's Medical Center Corporation Methods for treating malaria using potassium channel inhibitors
EP3106155A1 (en) * 2015-06-15 2016-12-21 Universite d'Aix Marseille Treatment and diagnosis of hereditary xerocytosis
US11439607B2 (en) * 2016-10-25 2022-09-13 Paracelsus Neuroscience I, LLC Use of senicapoc for treatment of neuropathic pain
WO2018162426A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment and diagnosis of hereditary xerocytosis
CN112020353A (zh) * 2019-03-29 2020-12-01 深圳仁泰医药科技有限公司 2,2-双(4-氟苯基)-2-苯乙酰胺的晶型a及其制备方法和应用
US20230045322A1 (en) * 2019-07-29 2023-02-09 Paracelsus Neuroscience II, LLC Use of senicapoc for treatment of stroke
US20230248672A1 (en) * 2020-07-14 2023-08-10 Adimabio Llc Compositions comprising gardos channel antagonists and their uses
US20240024335A1 (en) 2020-12-11 2024-01-25 Sanquin IP B.V. Treatment and prevention of anaemia of inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
DE69734983T2 (de) 1996-03-20 2006-09-07 President And Fellows Of Harvard College, Cambridge Triarylmethanverbindungen zur behandlung von krebs, aktinischer keratose und kaposisarkom

Also Published As

Publication number Publication date
HK1045262A1 (en) 2002-11-22
CN1344158A (zh) 2002-04-10
AP1465A (en) 2005-09-22
IL145012A0 (en) 2002-06-30
BR0008416A (pt) 2002-01-29
AP2001002268A0 (en) 2001-09-30
HK1045262B (zh) 2005-07-29
WO2000050026A1 (en) 2000-08-31
AU762039B2 (en) 2003-06-19
KR20020002393A (ko) 2002-01-09
DE60036093D1 (de) 2007-10-04
JP4038337B2 (ja) 2008-01-23
JP2002537331A (ja) 2002-11-05
CN1193748C (zh) 2005-03-23
KR100705726B1 (ko) 2007-04-11
CA2371857A1 (en) 2000-08-31
CA2371857C (en) 2008-07-29
US6288122B1 (en) 2001-09-11
IL145012A (en) 2006-12-10
DE60036093T2 (de) 2008-05-15
ES2291191T3 (es) 2008-03-01
EP1158971A4 (en) 2003-04-16
EP1158971A1 (en) 2001-12-05
EP1158971B1 (en) 2007-08-22
JP2007262075A (ja) 2007-10-11
ATE370728T1 (de) 2007-09-15
AU2880700A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
OA11838A (en) Gardos channel antagonists.
US4400394A (en) Benzylidene derivatives
BR9908084B1 (pt) composto 2-fenil-1-(3,4-diidróxi-5-nitrofenil)-1-etanona, composição farmacêutica, e, uso de um composto.
US20100056637A1 (en) Treatment methods using triaryl methane compounds
PL154186B1 (en) Method for manufacturing arylic derivatives of the hydroxamic acid
JPH04270261A (ja) イソプレノイドホスホリパーゼ▲ａ２▼阻害剤およびそれを包含する製剤
JPS61218570A (ja) 新規複素環アミド化合物、およびそれらを含有する医薬組成物
US4797391A (en) ((5,6-dichloro-3-oxo-9,9a-disubstituted-2,3,9,9a-tetrahydrofluoren-7-yl)oxy)alkanoic acids and alkanimidamides
CS267551B1 (en) Pharmaceutical agents for asthma treatment and method of effective substance production
US4835313A (en) (5,6-dichloro-3-oxo-9α-propyl-2,3,9,9α-tetrahydrofluoren-7-yl) alkanimidamides
Abood et al. Carbamate ester latentiation of physiologically active amines
AU2006320567A1 (en) Inhibitors of kynurenine aminotransferase and uses therefor
KR950013577B1 (ko) 카르복스아미드 유도체
US4562206A (en) Orally effective inotropic compounds
US3856951A (en) Substituted benzoic acid hypoliphemic agents
ZA200106847B (en) Gardos channel antagonists.
US4418074A (en) 2,6 Di(t-butyl)-4-(2'-pyrrol)-phenol and anti-inflammatory use thereof
US20060100289A1 (en) Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
JPS6330283B2 (zh)
US3457354A (en) Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
JPH08325154A (ja) 安息香酸誘導体およびそれを有効成分として含有するホスホリパーゼａ２阻害剤
US4146728A (en) Esters of 2-[4-(4-chlorobenzoyl)-phenoxy-2-methyl-propionic acid with bis-(hydroxyalkylthio)-alkanes
US3740395A (en) Ethyl 10 - (beta-morpholylpropionyl)-phenthiazine-2-carbamate hydrochloride
US3673197A (en) Exo-dibicycloalkane carboxamides
JPH0374673B2 (zh)